Open AccessSeroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Author(s) -
Caroline M. Hsu,
Daniel E. Weiner,
Harold J. Manley,
Gideon Aweh,
Vladimir Ladik,
Jill Frament,
Dana C. Miskulin,
Christos Argyropoulos,
Kenneth Abreo,
Andrew Chin,
Reginald Gladish,
Loay Salman,
Dianna A. Johnson,
Eduardo Lacson
Publication year - 2022
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.12250921
Subject(s) - medicine , interquartile range , titer , vaccination , dialysis , immunology , antibody titer , antibody
Although most patients receiving maintenance dialysis exhibit initial seroresponse to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, concerns exist regarding the durability of this antibody response. This study evaluated seroresponse over time.